Nano Nuclear Energy Files S-1 for Public Offering

TL;DR

Nano Nuclear Energy is going public, filing S-1 on 10/21/24. Big energy play incoming.

AI Summary

Nano Nuclear Energy Inc. filed an S-1 form on October 21, 2024, indicating plans for a public offering. The company, incorporated in Nevada, is based in New York and operates in the electric services sector. Financial data for periods ending June 30, 2024, and September 30, 2023, are included in the filing.

Why It Matters

This S-1 filing signals Nano Nuclear Energy's intention to raise capital through a public offering, which could significantly impact its growth and future operations in the energy sector.

Risk Assessment

Risk Level: medium — As a company pursuing a public offering, Nano Nuclear Energy faces inherent risks associated with market reception, regulatory hurdles, and the execution of its business plan.

Key Numbers

• 333-282750 — SEC File Number (Identifies this specific SEC filing)
• 241383431 — Film Number (Internal SEC processing number)

Key Players & Entities

• Nano Nuclear Energy Inc. (company) — Filer of the S-1 document
• October 21, 2024 (date) — Filing date of the S-1
• Nevada (location) — State of incorporation
• New York (location) — Business and mailing address
• 4911 (industry_code) — Standard Industrial Classification for Electric Services
• June 30, 2024 (date) — Financial reporting period end
• September 30, 2023 (date) — Financial reporting period end

FAQ

Key Financial Figures

• $21.45 — ) based on an assumed offering price of $21.45 per Unit, which was the last reported s
• $2,415,000 — writing discounts will be approximately $2,415,000 and the additional proceeds to us, befo
• $4,140,000 — t option exercise will be approximately $4,140,000. The underwriters expect to deliver th
• $1.71 million — ry building in Oak Ridge, Tennessee for $1.71 million to house our Nuclear Technology Headqua
• $1 million — anticipate would require approximately $1 million over the next twelve months to recruit
• $8 million — imated expenditures to be approximately $8 million. This allocation comprises approximatel
• $6 million — This allocation comprises approximately $6 million dedicated to the research and developme
• $2 million — e a strategic investment. The remaining $2 million is earmarked for miscellaneous costs es
• $14,942,045 — have incurred accumulated net losses of $14,942,045 since inception through June 30, 2024.

Filing Documents

• forms-1.htm (S-1) — 2369KB
• ex1-1.htm (EX-1.1) — 276KB
• ex4-4.htm (EX-4.4) — 84KB
• ex4-6.htm (EX-4.6) — 226KB
• ex5-1.htm (EX-5.1) — 28KB
• ex10-13.htm (EX-10.13) — 165KB
• ex21-1.htm (EX-21.1) — 3KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 39KB
• formdrs_001.jpg (GRAPHIC) — 7KB
• formdrs_002.jpg (GRAPHIC) — 20KB
• formdrs_003.jpg (GRAPHIC) — 12KB
• formdrs_004.jpg (GRAPHIC) — 12KB
• formdrs_005.jpg (GRAPHIC) — 15KB
• formdrs_006.jpg (GRAPHIC) — 14KB
• formdrs_007.jpg (GRAPHIC) — 14KB
• formdrs_008.jpg (GRAPHIC) — 17KB
• formdrs_009.jpg (GRAPHIC) — 15KB
• formdrs_010.jpg (GRAPHIC) — 101KB
• formdrs_011.jpg (GRAPHIC) — 14KB
• formdrs_012.jpg (GRAPHIC) — 14KB
• formdrs_013.jpg (GRAPHIC) — 14KB
• formdrs_014.jpg (GRAPHIC) — 17KB
• ex5-1_001.jpg (GRAPHIC) — 36KB
• ex5-1_002.jpg (GRAPHIC) — 5KB
• 0001493152-24-041765.txt ( ) — 8116KB
• nne-20240630.xsd (EX-101.SCH) — 28KB
• nne-20240630_cal.xml (EX-101.CAL) — 34KB
• nne-20240630_def.xml (EX-101.DEF) — 159KB
• nne-20240630_lab.xml (EX-101.LAB) — 273KB
• nne-20240630_pre.xml (EX-101.PRE) — 211KB
• forms-1_htm.xml (XML) — 725KB

Underwriting

Underwriting discounts (1) $ $ Proceeds to us, before expenses (2) $ $ (1) Represents underwriting discounts equal to (i) seven percent (7%) per Unit (or $[_____] per Unit), which is the underwriting discounts we have agreed to pay to the underwriters. (2) Does not include a non-accountable expense allowance equal to one percent (1%) of the gross proceeds of this offering, payable to the representative of the underwriters, or the reimbursement of certain expenses of the underwriters. We have also agreed to issue warrants to the representative of the underwriters to purchase a number of shares of common stock equal to seven percent (7%) of the total number of shares of common stock included as part of the Units sold in this offering at an exercise price equal to one hundred and twenty-five percent (125%) of the public offering price of the Units sold in this offering. For a description of the other terms of compensation to be received by the underwriters, see " Underwriting ." We have granted a 30-day option to the representative of the underwriters to purchase up to an additional 209,790 shares of common stock and/or additional Warrants to purchase up to 104,895 shares of common stock solely to cover over-allotments, if any. If the representative of the underwriters exercises the option in full, the total underwriting discounts will be approximately $2,415,000 and the additional proceeds to us, before expenses, from the over-allotment option exercise will be approximately $4,140,000. The underwriters expect to deliver the Units to purchasers on or about [], 2024. The Benchmark Company The date of this prospectus is [], 2024 Creating the Next Generation of Advanced Nuclear Fuels and Developing Smaller, Cheaper and Safer Portable Clean Energy Solutions Renderings of proposed "Zeus" Microreactor Renderings of proposed "Odin" Microreactor Proposed HALEU Fuel Processing Facility TABLE OF CONTENTS PAGE PROSPECTUS SUMMARY 1 THE OFFERING

USE OF PROCEEDS

USE OF PROCEEDS 37 DIVIDEND POLICY 37 CAPITALIZATION 38

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 41

BUSINESS

BUSINESS 49 MANAGEMENT 74 EXECUTIVE AND DIRECTOR COMPENSATION 84 PRINCIPAL STOCKHOLDERS 89 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 90

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 92 SHARES ELIGIBLE FOR FUTURE SALE 98 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 100

UNDERWRITING

UNDERWRITING 104 LEGAL MATTERS 108 EXPERTS 108 WHERE YOU CAN FIND ADDITIONAL INFORMATION 108 INDEX TO FINANCIAL STATEMENTS F-1 You should only rely on the information contained in this prospectus and in any free writing prospectus prepared by or on behalf of us and delivered or made available to you. Neither we nor the underwriters have authorized anyone to provide you with additional or different information. We are offering to sell, and seeking offers to buy, the Units only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or a free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of the Units offered hereby. Our business, financial condition, operating results, and prospects may have changed since that date. For investors outside the United States : Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United restrictions relating to, the offering of the Units, and the distribution of this prospectus outside of the United States. i INDUSTRY AND MARKET DATA Unless otherwise indicated, information in this prospectus concerning economic conditions, our industry, our markets and our competitive position is based on a variety of sources, including information from third-party industry analysts and publications and our own estimates and research. Some of the industry and market data contained in this prospectus are based on third-party industry publications. This information involves a number of assumptions, estimates and limitations. The industry publications, surveys and forecasts and other public information generally indicate or suggest that th

View Full Filing

View this S-1 filing on SEC EDGAR